{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:29:24Z","timestamp":1793996964241,"version":"4.8.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41577-025-01136-7","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:07:58Z","timestamp":1739437678000},"page":"542-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immune-mediated strategies to solving the HIV reservoir problem"],"prefix":"10.1038","volume":"25","author":[{"given":"Deanna A.","family":"Kulpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Paiardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-2470","authenticated-orcid":false,"given":"Guido","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"1136_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/COH.0000000000000487","volume":"13","author":"M Pino","year":"2018","unstructured":"Pino, M., Paiardini, M. & Marconi, V. C. Progress in achieving long-term HIV remission. Curr. Opin. HIV AIDS 13, 435\u2013445 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S2055-6640(20)30275-2","volume":"5","author":"J Vanhamel","year":"2019","unstructured":"Vanhamel, J., Bruggemans, A. & Debyser, Z. Establishment of latent HIV-1 reservoirs: what do we really know? J. Virus Erad. 5, 3\u20139 (2019).","journal-title":"J. Virus Erad."},{"key":"1136_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature13594","volume":"512","author":"JB Whitney","year":"2014","unstructured":"Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74\u201377 (2014).","journal-title":"Nature"},{"key":"1136_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.chom.2022.12.002","volume":"31","author":"X Lian","year":"2023","unstructured":"Lian, X. et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe 31, 83\u201396 (2023).","journal-title":"Cell Host Microbe"},{"key":"1136_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/COH.0000000000000441","volume":"13","author":"HH Kuo","year":"2018","unstructured":"Kuo, H. H. & Lichterfeld, M. Recent progress in understanding HIV reservoirs. Curr. Opin. HIV AIDS 13, 137\u2013142 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","volume":"21","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz, R. J., Scott, H. & Deeks, S. G. Prevention, treatment and cure of HIV infection. Nat. Rev. Microbiol. 21, 657\u2013670 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1136_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06843-5","volume":"9","author":"DB Reeves","year":"2018","unstructured":"Reeves, D. B. et al. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat. Commun. 9, 4811 (2018).","journal-title":"Nat. Commun."},{"key":"1136_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49369-9","volume":"15","author":"TT Immonen","year":"2024","unstructured":"Immonen, T. T. et al. No evidence for ongoing replication on ART in SIV-infected macaques. Nat. Commun. 15, 5093 (2024).","journal-title":"Nat. Commun."},{"key":"1136_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004010","volume":"10","author":"MF Kearney","year":"2014","unstructured":"Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).","journal-title":"PLoS Pathog."},{"key":"1136_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1034\/j.1600-065x.2001.1830112.x","volume":"183","author":"DT Evans","year":"2001","unstructured":"Evans, D. T. & Desrosiers, R. C. Immune evasion strategies of the primate lentiviruses. Immunol. Rev. 183, 141\u2013158 (2001).","journal-title":"Immunol. Rev."},{"key":"1136_CR11","doi-asserted-by":"publisher","first-page":"S309","DOI":"10.1086\/655653","volume":"202","author":"CL Boutwell","year":"2010","unstructured":"Boutwell, C. L., Rolland, M. M., Herbeck, J. T., Mullins, J. I. & Allen, T. M. Viral evolution and escape during acute HIV-1 infection. J. Infect. Dis. 202, S309\u2013S314 (2010).","journal-title":"J. Infect. Dis."},{"key":"1136_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ni.3156","volume":"16","author":"V Simon","year":"2015","unstructured":"Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546\u2013553 (2015).","journal-title":"Nat. Immunol."},{"key":"1136_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1473-3099(04)01056-4","volume":"4","author":"DA Garber","year":"2004","unstructured":"Garber, D. A., Silvestri, G. & Feinberg, M. B. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4, 397\u2013413 (2004).","journal-title":"Lancet Infect. Dis."},{"key":"1136_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.1254194","volume":"345","author":"F Maldarelli","year":"2014","unstructured":"Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179\u2013183 (2014).","journal-title":"Science"},{"key":"1136_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.1256304","volume":"345","author":"TA Wagner","year":"2014","unstructured":"Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570\u2013573 (2014).","journal-title":"Science"},{"key":"1136_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893\u2013900 (2009).","journal-title":"Nat. Med."},{"key":"1136_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cell.2020.03.005","volume":"181","author":"DM Margolis","year":"2020","unstructured":"Margolis, D. M. et al. Curing HIV: seeking to target and clear persistent infection. Cell 181, 189\u2013206 (2020).","journal-title":"Cell"},{"key":"1136_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0140-6736(20)30264-6","volume":"395","author":"SR Lewin","year":"2020","unstructured":"Lewin, S. R. & Rasmussen, T. A. Kick and kill for HIV latency. Lancet 395, 844\u2013846 (2020).","journal-title":"Lancet"},{"key":"1136_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jmp.12613","volume":"51","author":"K Tanaka","year":"2022","unstructured":"Tanaka, K., Kim, Y., Roche, M. & Lewin, S. R. The role of latency reversal in HIV cure strategies. J. Med. Primatol. 51, 278\u2013283 (2022).","journal-title":"J. Med. Primatol."},{"key":"1136_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","volume":"23","author":"Y Kim","year":"2018","unstructured":"Kim, Y., Anderson, J. L. & Lewin, S. R. Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: strategies to eliminate latent HIV. Cell Host Microbe 23, 14\u201326 (2018).","journal-title":"Cell Host Microbe"},{"key":"1136_CR21","doi-asserted-by":"publisher","first-page":"e00138","DOI":"10.1128\/JVI.00138-21","volume":"95","author":"A Alto","year":"2021","unstructured":"Alto, A. et al. The combination of venetoclax and ixazomib selectively and efficiently kills HIV-infected cell lines but has unacceptable toxicity in primary cell models. J. Virol. 95, e00138-21 (2021).","journal-title":"J. Virol."},{"key":"1136_CR22","doi-asserted-by":"publisher","first-page":"e00107","DOI":"10.1128\/CMR.00107-19","volume":"33","author":"AP Chandrasekar","year":"2019","unstructured":"Chandrasekar, A. P., Cummins, N. W. & Badley, A. D. The role of the BCL-2 family of proteins in HIV-1 pathogenesis and persistence. Clin. Microbiol. Rev. 33, e00107\u2013e00119 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"1136_CR23","doi-asserted-by":"publisher","first-page":"e00012","DOI":"10.1128\/JVI.00012-17","volume":"91","author":"NW Cummins","year":"2017","unstructured":"Cummins, N. W. et al. Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition. J. Virol. 91, e00012\u2013e00017 (2017).","journal-title":"J. Virol."},{"key":"1136_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02425-20","volume":"95","author":"Y Ren","year":"2021","unstructured":"Ren, Y. et al. Selective BCL-XL antagonists eliminate infected cells from a primary-cell model of HIV latency but not from ex vivo reservoirs. J. Virol. 95, e0242520 (2021).","journal-title":"J. Virol."},{"key":"1136_CR25","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1172\/JCI132374","volume":"130","author":"Y Ren","year":"2020","unstructured":"Ren, Y. et al. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J. Clin. Invest. 130, 2542\u20132559 (2020).","journal-title":"J. Clin. Invest."},{"key":"1136_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482\u2013485 (2012).","journal-title":"Nature"},{"key":"1136_CR27","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1074\/jbc.M807898200","volume":"284","author":"X Contreras","year":"2009","unstructured":"Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782\u20136789 (2009).","journal-title":"J. Biol. Chem."},{"key":"1136_CR28","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1182\/blood.V98.10.3006","volume":"98","author":"J Kulkosky","year":"2001","unstructured":"Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006\u20133015 (2001).","journal-title":"Blood"},{"key":"1136_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/cid\/cix201","volume":"64","author":"L Vibholm","year":"2017","unstructured":"Vibholm, L. et al. Short-course Toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection. Clin. Infect. Dis. 64, 1686\u20131695 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"1136_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/cid\/cit813","volume":"58","author":"AM Spivak","year":"2014","unstructured":"Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883\u2013890 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"1136_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2019.03.004","volume":"38","author":"JM Zerbato","year":"2019","unstructured":"Zerbato, J. M., Purves, H. V., Lewin, S. R. & Rasmussen, T. A. Between a shock and a hard place: challenges and developments in HIV latency reversal. Curr. Opin. Virol. 38, 1\u20139 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"1136_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-1946-0","volume":"578","author":"JB McBrien","year":"2020","unstructured":"McBrien, J. B. et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells. Nature 578, 154\u2013159 (2020).","journal-title":"Nature"},{"key":"1136_CR33","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2023.03.010","volume":"56","author":"S Mutascio","year":"2023","unstructured":"Mutascio, S. et al. CD8+ T cells promote HIV latency by remodeling CD4+ T cell metabolism to enhance their survival, quiescence, and stemness. Immunity 56, 1132\u20131147 (2023).","journal-title":"Immunity"},{"key":"1136_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008821","volume":"16","author":"M Zanoni","year":"2020","unstructured":"Zanoni, M. et al. Innate, non-cytolytic CD8+ T cell-mediated suppression of HIV replication by MHC-independent inhibition of virus transcription. PLoS Pathog. 16, e1008821 (2020).","journal-title":"PLoS Pathog."},{"key":"1136_CR35","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.4049\/jimmunol.1801379","volume":"205","author":"J Wallace","year":"2020","unstructured":"Wallace, J., Narasipura, S. D., Sha, B. E., French, A. L. & Al-Harthi, L. Canonical Wnts mediate CD8+ T cell noncytolytic anti-HIV-1 activity and correlate with HIV-1 clinical status. J. Immunol. 205, 2046\u20132055 (2020).","journal-title":"J. Immunol."},{"key":"1136_CR36","doi-asserted-by":"publisher","first-page":"a032102","DOI":"10.1101\/cshperspect.a032102","volume":"10","author":"S Crotty","year":"2018","unstructured":"Crotty, S. Do memory CD4 T cells keep their cell-type programming: plasticity versus fate commitment? Complexities of interpretation due to the heterogeneity of memory CD4 T cells, including T follicular helper cells. Cold Spring Harb. Perspect. Biol. 10, a032102 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1136_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaci.2022.08.023","volume":"150","author":"E Grydziuszko","year":"2022","unstructured":"Grydziuszko, E., Phelps, A., Bruton, K., Jordana, M. & Koenig, J. F. E. Heterogeneity, subsets, and plasticity of T follicular helper cells in allergy. J. Allergy Clin. Immunol. 150, 990\u2013998 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1136_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/cr.2009.138","volume":"20","author":"J Zhu","year":"2010","unstructured":"Zhu, J. & Paul, W. E. Heterogeneity and plasticity of T helper cells. Cell Res. 20, 4\u201312 (2010).","journal-title":"Cell Res."},{"key":"1136_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150794","volume":"6","author":"MR Pinzone","year":"2021","unstructured":"Pinzone, M. R. et al. Naive infection predicts reservoir diversity and is a formidable hurdle to HIV eradication. JCI Insight 6, e150794 (2021).","journal-title":"JCI Insight"},{"key":"1136_CR40","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1128\/JVI.73.9.7108-7116.1999","volume":"73","author":"M Dalod","year":"1999","unstructured":"Dalod, M. et al. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8+ responses in HIV type 1-infected patients: comparison with anti-Epstein\u2013Barr virus responses and changes during antiretroviral therapy. J. Virol. 73, 7108\u20137116 (1999).","journal-title":"J. Virol."},{"key":"1136_CR41","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.4049\/jimmunol.165.2.1082","volume":"165","author":"JC Gea-Banacloche","year":"2000","unstructured":"Gea-Banacloche, J. C. et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J. Immunol. 165, 1082\u20131092 (2000).","journal-title":"J. Immunol."},{"key":"1136_CR42","doi-asserted-by":"publisher","first-page":"11983","DOI":"10.1128\/JVI.75.24.11983-11991.2001","volume":"75","author":"MR Betts","year":"2001","unstructured":"Betts, M. R. et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983\u201311991 (2001).","journal-title":"J. Virol."},{"key":"1136_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003878","volume":"10","author":"R Batorsky","year":"2014","unstructured":"Batorsky, R., Sergeev, R. A. & Rouzine, I. M. The route of HIV escape from immune response targeting multiple sites is determined by the cost-benefit tradeoff of escape mutations. PLoS Comput. Biol. 10, e1003878 (2014).","journal-title":"PLoS Comput. Biol."},{"key":"1136_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000103","volume":"4","author":"CL Althaus","year":"2008","unstructured":"Althaus, C. L. & De Boer, R. J. Dynamics of immune escape during HIV\/SIV infection. PLoS Comput. Biol. 4, e1000103 (2008).","journal-title":"PLoS Comput. Biol."},{"key":"1136_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006135","volume":"12","author":"ER Roberts","year":"2016","unstructured":"Roberts, E. R. et al. Collapse of cytolytic potential in SIV-specific CD8+ T cells following acute SIV infection in rhesus macaques. PLoS Pathog. 12, e1006135 (2016).","journal-title":"PLoS Pathog."},{"key":"1136_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004251","volume":"10","author":"M Buggert","year":"2014","unstructured":"Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 10, e1004251 (2014).","journal-title":"PLoS Pathog."},{"key":"1136_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imr.12066","volume":"254","author":"AA Okoye","year":"2013","unstructured":"Okoye, A. A. & Picker, L. J. CD4+ T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol. Rev. 254, 54\u201364 (2013).","journal-title":"Immunol. Rev."},{"key":"1136_CR48","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.4049\/jimmunol.171.9.4473","volume":"171","author":"JL Petersen","year":"2003","unstructured":"Petersen, J. L., Morris, C. R. & Solheim, J. C. Virus evasion of MHC class I molecule presentation. J. Immunol. 171, 4473\u20134478 (2003).","journal-title":"J. Immunol."},{"key":"1136_CR49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/34929","volume":"391","author":"KL Collins","year":"1998","unstructured":"Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D. & Baltimore, D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397\u2013401 (1998).","journal-title":"Nature"},{"key":"1136_CR50","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1073\/pnas.050567397","volume":"97","author":"SA Migueles","year":"2000","unstructured":"Migueles, S. A. et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl Acad. Sci. USA 97, 2709\u20132714 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1136_CR51","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1128\/JVI.74.4.2023-2028.2000","volume":"74","author":"JC de Quiros","year":"2000","unstructured":"de Quiros, J. C. et al. Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8+ T cells and associated with a proliferative response to p24 antigen. J. Virol. 74, 2023\u20132028 (2000).","journal-title":"J. Virol."},{"key":"1136_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm0496-405","volume":"2","author":"RA Kaslow","year":"1996","unstructured":"Kaslow, R. A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2, 405\u2013411 (1996).","journal-title":"Nat. Med."},{"key":"1136_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/infdis\/jiaa333","volume":"223","author":"C Kaseke","year":"2021","unstructured":"Kaseke, C., Tano-Menka, R., Senjobe, F. & Gaiha, G. D. The emerging role for CTL epitope specificity in HIV cure efforts. J. Infect. Dis. 223, 32\u201337 (2021).","journal-title":"J. Infect. Dis."},{"key":"1136_CR54","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1126\/science.aav5095","volume":"364","author":"GD Gaiha","year":"2019","unstructured":"Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480\u2013484 (2019).","journal-title":"Science"},{"key":"1136_CR55","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1172\/JCI98463","volume":"128","author":"MP Martin","year":"2018","unstructured":"Martin, M. P. et al. Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J. Clin. Invest. 128, 1903\u20131912 (2018).","journal-title":"J. Clin. Invest."},{"key":"1136_CR56","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bbagen.2015.01.003","volume":"1850","author":"EN Pawlak","year":"2015","unstructured":"Pawlak, E. N. & Dikeakos, J. D. HIV-1 Nef: a master manipulator of the membrane trafficking machinery mediating immune evasion. Biochim. Biophys. Acta 1850, 733\u2013741 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"1136_CR57","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1091\/mbc.e11-11-0928","volume":"23","author":"JD Dikeakos","year":"2012","unstructured":"Dikeakos, J. D. et al. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I. Mol. Biol. Cell 23, 2184\u20132197 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"1136_CR58","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0092-8674(02)01162-5","volume":"111","author":"AD Blagoveshchenskaya","year":"2002","unstructured":"Blagoveshchenskaya, A. D., Thomas, L., Feliciangeli, S. F., Hung, C. H. & Thomas, G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 111, 853\u2013866 (2002).","journal-title":"Cell"},{"key":"1136_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000131","volume":"4","author":"MR Schaefer","year":"2008","unstructured":"Schaefer, M. R., Wonderlich, E. R., Roeth, J. F., Leonard, J. A. & Collins, K. L. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common \u03b2-COP-dependent pathway in T cells. PLoS Pathog. 4, e1000131 (2008).","journal-title":"PLoS Pathog."},{"key":"1136_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1126\/science.1232685","volume":"340","author":"R Apps","year":"2013","unstructured":"Apps, R. et al. Influence of HLA-C expression level on HIV control. Science 340, 87\u201391 (2013).","journal-title":"Science"},{"key":"1136_CR61","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.4049\/jimmunol.1103472","volume":"188","author":"ME Blais","year":"2012","unstructured":"Blais, M. E. et al. High frequency of HIV mutations associated with HLA-C suggests enhanced HLA-C-restricted CTL selective pressure associated with an AIDS-protective polymorphism. J. Immunol. 188, 4663\u20134670 (2012).","journal-title":"J. Immunol."},{"key":"1136_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/COH.0000000000000124","volume":"10","author":"BJ Macatangay","year":"2015","unstructured":"Macatangay, B. J. & Rinaldo, C. R. Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help? Curr. Opin. HIV AIDS 10, 55\u201360 (2015).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature14053","volume":"517","author":"K Deng","year":"2015","unstructured":"Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381\u2013385 (2015).","journal-title":"Nature"},{"key":"1136_CR64","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57246","volume":"9","author":"JA Warren","year":"2020","unstructured":"Warren, J. A. et al. The HIV-1 latent reservoir is largely sensitive to circulating T cells. eLife 9, e57246 (2020).","journal-title":"eLife"},{"key":"1136_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41564-022-01311-9","volume":"8","author":"M Statzu","year":"2023","unstructured":"Statzu, M. et al. CD8+ lymphocytes do not impact SIV reservoir establishment under ART. Nat. Microbiol. 8, 299\u2013308 (2023).","journal-title":"Nat. Microbiol."},{"key":"1136_CR66","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1172\/JCI97555","volume":"128","author":"SH Huang","year":"2018","unstructured":"Huang, S. H. et al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J. Clin. Invest. 128, 876\u2013889 (2018).","journal-title":"J. Clin. Invest."},{"key":"1136_CR67","doi-asserted-by":"publisher","first-page":"eaaw5589","DOI":"10.1126\/scitranslmed.aaw5589","volume":"11","author":"MR Abrahams","year":"2019","unstructured":"Abrahams, M. R. et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci. Transl. Med. 11, eaaw5589 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1136_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136648","volume":"6","author":"RL Rutishauser","year":"2021","unstructured":"Rutishauser, R. L. et al. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight 6, e136648 (2021).","journal-title":"JCI Insight"},{"key":"1136_CR69","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/s41590-024-01875-0","volume":"25","author":"Z Strongin","year":"2024","unstructured":"Strongin, Z. et al. Distinct SIV-specific CD8+ T cells in the lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence. Nat. Immunol. 25, 1245\u20131256 (2024).","journal-title":"Nat. Immunol."},{"key":"1136_CR70","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41579-024-01010-8","volume":"22","author":"M Armani-Tourret","year":"2024","unstructured":"Armani-Tourret, M. et al. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat. Rev. Microbiol. 22, 328\u2013344 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1136_CR71","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41590-022-01371-3","volume":"24","author":"VH Wu","year":"2023","unstructured":"Wu, V. H. et al. Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4+ T cell reservoir. Nat. Immunol. 24, 359\u2013370 (2023).","journal-title":"Nat. Immunol."},{"key":"1136_CR72","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1172\/JCI124291","volume":"129","author":"KB Einkauf","year":"2019","unstructured":"Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest. 129, 988\u2013998 (2019).","journal-title":"J. Clin. Invest."},{"key":"1136_CR73","doi-asserted-by":"publisher","first-page":"25891","DOI":"10.1073\/pnas.1910334116","volume":"116","author":"SC Patro","year":"2019","unstructured":"Patro, S. C. et al. Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proc. Natl Acad. Sci. USA 116, 25891\u201325899 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1136_CR74","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.cell.2024.01.037","volume":"187","author":"M Armani-Tourret","year":"2024","unstructured":"Armani-Tourret, M. et al. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-\u03b12a. Cell 187, 1238\u20131254 (2024).","journal-title":"Cell"},{"key":"1136_CR75","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/infdis\/jiad595","volume":"229","author":"J Blazkova","year":"2024","unstructured":"Blazkova, J. et al. Immunologic and virologic parameters associated with human immunodeficiency virus (HIV) DNA reservoir size in people with HIV receiving antiretroviral therapy. J. Infect. Dis. 229, 1770\u20131780 (2024).","journal-title":"J. Infect. Dis."},{"key":"1136_CR76","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241091","volume":"221","author":"W Sun","year":"2024","unstructured":"Sun, W. et al. Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection. J. Exp. Med. 221, e20241091 (2024).","journal-title":"J. Exp. Med."},{"key":"1136_CR77","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/v13081451","volume":"13","author":"G Khoury","year":"2021","unstructured":"Khoury, G., Kulpa, D. A. & Parsons, M. S. Potential utility of natural killer cells for eliminating cells harboring reactivated latent HIV-1 following the removal of CD8+ T cell-mediated pro-latency effect(s). Viruses 13, 1451 (2021).","journal-title":"Viruses"},{"key":"1136_CR78","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s41564-023-01349-3","volume":"8","author":"RT Veenhuis","year":"2023","unstructured":"Veenhuis, R. T. et al. Monocyte-derived macrophages contain persistent latent HIV reservoirs. Nat. Microbiol. 8, 833\u2013844 (2023).","journal-title":"Nat. Microbiol."},{"key":"1136_CR79","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.3389\/fmicb.2019.02828","volume":"10","author":"Z Kruize","year":"2019","unstructured":"Kruize, Z. & Kootstra, N. A. The role of macrophages in HIV-1 persistence and pathogenesis. Front. Microbiol. 10, 2828 (2019).","journal-title":"Front. Microbiol."},{"key":"1136_CR80","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1182\/blood-2007-12-130070","volume":"111","author":"F Groot","year":"2008","unstructured":"Groot, F., Welsch, S. & Sattentau, Q. J. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111, 4660\u20134663 (2008).","journal-title":"Blood"},{"key":"1136_CR81","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.chom.2023.08.020","volume":"31","author":"R Banga","year":"2023","unstructured":"Banga, R. et al. Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART. Cell Host Microbe 31, 1714\u20131731 (2023).","journal-title":"Cell Host Microbe"},{"key":"1136_CR82","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/jcm9082661","volume":"9","author":"R Abrahem","year":"2020","unstructured":"Abrahem, R. et al. The role of dendritic cells in TB and HIV Infection. J. Clin. Med. 9, 2661 (2020).","journal-title":"J. Clin. Med."},{"key":"1136_CR83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1530\/ror.0.0030042","volume":"3","author":"CJ Miller","year":"1998","unstructured":"Miller, C. J. Host and viral factors influencing heterosexual HIV transmission. Rev. Reprod. 3, 42\u201351 (1998).","journal-title":"Rev. Reprod."},{"key":"1136_CR84","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.it.2013.10.003","volume":"35","author":"O Manches","year":"2014","unstructured":"Manches, O., Frleta, D. & Bhardwaj, N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol. 35, 114\u2013122 (2014).","journal-title":"Trends Immunol."},{"key":"1136_CR85","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/ni841","volume":"3","author":"SG Turville","year":"2002","unstructured":"Turville, S. G. et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3, 975\u2013983 (2002).","journal-title":"Nat. Immunol."},{"key":"1136_CR86","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nri1960","volume":"6","author":"L Wu","year":"2006","unstructured":"Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6, 859\u2013868 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"1136_CR87","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1097\/QAD.0000000000001645","volume":"31","author":"J Mikulak","year":"2017","unstructured":"Mikulak, J., Oriolo, F., Zaghi, E., Di Vito, C. & Mavilio, D. Natural killer cells in HIV-1 infection and therapy. AIDS 31, 2317\u20132330 (2017).","journal-title":"AIDS"},{"key":"1136_CR88","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/imm.13039","volume":"156","author":"LY Bastidas-Legarda","year":"2019","unstructured":"Bastidas-Legarda, L. Y. & Khakoo, S. I. Conserved and variable natural killer cell receptors: diverse approaches to viral infections. Immunology 156, 319\u2013328 (2019).","journal-title":"Immunology"},{"key":"1136_CR89","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/ni1102-1019","volume":"3","author":"JW Yewdell","year":"2002","unstructured":"Yewdell, J. W. & Hill, A. B. Viral interference with antigen presentation. Nat. Immunol. 3, 1019\u20131025 (2002).","journal-title":"Nat. Immunol."},{"key":"1136_CR90","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1097\/QAD.0000000000002011","volume":"32","author":"DN Forthal","year":"2018","unstructured":"Forthal, D. N. & Finzi, A. Antibody-dependent cellular cytotoxicity in HIV infection. AIDS 32, 2439\u20132451 (2018).","journal-title":"AIDS"},{"key":"1136_CR91","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/infdis\/jiw555","volume":"215","author":"G Ferrari","year":"2017","unstructured":"Ferrari, G., Pollara, J., Tomaras, G. D. & Haynes, B. F. Humoral and innate antiviral immunity as tools to clear persistent HIV infection. J. Infect. Dis. 215, S152\u2013S159 (2017).","journal-title":"J. Infect. Dis."},{"key":"1136_CR92","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2019.01124","volume":"10","author":"C Manickam","year":"2019","unstructured":"Manickam, C., Shah, S. V., Nohara, J., Ferrari, G. & Reeves, R. K. Monkeying around: using non-human primate models to study NK cell biology in HIV infections. Front. Immunol. 10, 1124 (2019).","journal-title":"Front. Immunol."},{"key":"1136_CR93","doi-asserted-by":"publisher","first-page":"886562","DOI":"10.3389\/fimmu.2022.886562","volume":"13","author":"VA Vieira","year":"2022","unstructured":"Vieira, V. A., Herbert, N., Cromhout, G., Adland, E. & Goulder, P. Role of early life cytotoxic T lymphocyte and natural killer cell immunity in paediatric HIV cure\/remission in the anti-retroviral therapy era. Front. Immunol. 13, 886562 (2022).","journal-title":"Front. Immunol."},{"key":"1136_CR94","doi-asserted-by":"publisher","first-page":"111126","DOI":"10.1016\/j.celrep.2022.111126","volume":"40","author":"CA Hartana","year":"2022","unstructured":"Hartana, C. A. et al. Immune correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Rep. 40, 111126 (2022).","journal-title":"Cell Rep."},{"key":"1136_CR95","doi-asserted-by":"publisher","first-page":"eaax7350","DOI":"10.1126\/scitranslmed.aax7350","volume":"11","author":"P Garcia-Broncano","year":"2019","unstructured":"Garcia-Broncano, P. et al. Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Sci. Transl. Med. 11, eaax7350 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1136_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23189-7","volume":"12","author":"J Harper","year":"2021","unstructured":"Harper, J. et al. IL-21 and IFN\u03b1 therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques. Nat. Commun. 12, 2866 (2021).","journal-title":"Nat. Commun."},{"key":"1136_CR97","doi-asserted-by":"publisher","first-page":"a030304","DOI":"10.1101\/cshperspect.a030304","volume":"10","author":"M Nagasawa","year":"2018","unstructured":"Nagasawa, M., Spits, H. & Ros, X. R. Innate lymphoid cells (ILCs): cytokine hubs regulating immunity and tissue homeostasis. Cold Spring Harb. Perspect. Biol. 10, a030304 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1136_CR98","doi-asserted-by":"publisher","first-page":"12193","DOI":"10.3390\/ijms241512193","volume":"24","author":"S Moretti","year":"2023","unstructured":"Moretti, S. et al. HIV-1-host interaction in gut-associated lymphoid tissue (GALT): effects on local environment and comorbidities. Int. J. Mol. Sci. 24, 12193 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1136_CR99","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.immuni.2016.01.006","volume":"44","author":"HN Kloverpris","year":"2016","unstructured":"Kloverpris, H. N. et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity 44, 391\u2013405 (2016).","journal-title":"Immunity"},{"key":"1136_CR100","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter, G. et al. Long-term control of HIV by CCR5 \u039432\/\u039432 stem-cell transplantation. N. Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1136_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003347","volume":"9","author":"SA Yukl","year":"2013","unstructured":"Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).","journal-title":"PLoS Pathog."},{"key":"1136_CR102","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248 (2019).","journal-title":"Nature"},{"key":"1136_CR103","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","volume":"7","author":"RK Gupta","year":"2020","unstructured":"Gupta, R. K. et al. Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV 7, e340\u2013e347 (2020).","journal-title":"Lancet HIV"},{"key":"1136_CR104","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","volume":"186","author":"J Hsu","year":"2023","unstructured":"Hsu, J. et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell 186, 1115\u20131126 (2023).","journal-title":"Cell"},{"key":"1136_CR105","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"BO Jensen","year":"2023","unstructured":"Jensen, B. O. et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation. Nat. Med. 29, 583\u2013587 (2023).","journal-title":"Nat. Med."},{"key":"1136_CR106","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3390\/ijms24021563","volume":"24","author":"M Hussein","year":"2023","unstructured":"Hussein, M., Molina, M. A., Berkhout, B. & Herrera-Carrillo, E. A CRISPR-cas cure for HIV\/AIDS. Int. J. Mol. Sci. 24, 1563 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1136_CR107","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/COH.0000000000000666","volume":"16","author":"CD Pauza","year":"2021","unstructured":"Pauza, C. D., Huang, K. & Bordon, J. Advances in cell and gene therapy for HIV disease: it is good to be specific. Curr. Opin. HIV AIDS 16, 83\u201387 (2021).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR108","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/ijms25052771","volume":"25","author":"R Kitawi","year":"2024","unstructured":"Kitawi, R., Ledger, S., Kelleher, A. D. & Ahlenstiel, C. L. Advances in HIV gene therapy. Int. J. Mol. Sci. 25, 2771 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1136_CR109","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142421","volume":"131","author":"AE Swanstrom","year":"2021","unstructured":"Swanstrom, A. E. et al. Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy. J. Clin. Invest. 131, e142421 (2021).","journal-title":"J. Clin. Invest."},{"key":"1136_CR110","unstructured":"Veenhuis, R. T. et al. CD4+ depletion results in robust CNS rebound and larger macrophage reservoirs [CROI Abstract 129]. Abstracts from CROI 2022 Conference on Retroviruses and Opportunistic Infections (2022)."},{"key":"1136_CR111","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41586-022-05556-6","volume":"614","author":"IC Clark","year":"2023","unstructured":"Clark, I. C. et al. HIV silencing and cell survival signatures in infected T cell reservoirs. Nature 614, 318\u2013325 (2023).","journal-title":"Nature"},{"key":"1136_CR112","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-022-05538-8","volume":"614","author":"W Sun","year":"2023","unstructured":"Sun, W. et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature 614, 309\u2013317 (2023).","journal-title":"Nature"},{"key":"1136_CR113","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-020-0782-y","volume":"26","author":"J Harper","year":"2020","unstructured":"Harper, J. et al. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. Nat. Med. 26, 519\u2013528 (2020).","journal-title":"Nat. Med."},{"key":"1136_CR114","doi-asserted-by":"publisher","first-page":"eabh3034","DOI":"10.1126\/sciimmunol.abh3034","volume":"6","author":"SA Rahman","year":"2021","unstructured":"Rahman, S. A. et al. PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Sci. Immunol. 6, eabh3034 (2021).","journal-title":"Sci. Immunol."},{"key":"1136_CR115","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41591-023-02570-7","volume":"29","author":"A Dashti","year":"2023","unstructured":"Dashti, A. et al. AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques. Nat. Med. 29, 2535\u20132546 (2023).","journal-title":"Nat. Med."},{"key":"1136_CR116","doi-asserted-by":"publisher","first-page":"eaao4521","DOI":"10.1126\/scitranslmed.aao4521","volume":"10","author":"SY Lim","year":"2018","unstructured":"Lim, S. Y. et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci. Transl Med. 10, eaao4521 (2018).","journal-title":"Sci. Transl Med."},{"key":"1136_CR117","doi-asserted-by":"publisher","first-page":"e01163","DOI":"10.1128\/AAC.01163-19","volume":"63","author":"E Bekerman","year":"2019","unstructured":"Bekerman, E. et al. PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. Antimicrob. Agents Chemother. 63, e01163\u201319 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1136_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127717","volume":"4","author":"GQ Del Prete","year":"2019","unstructured":"Del Prete, G. Q. et al. TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia. JCI Insight 4, e127717 (2019).","journal-title":"JCI Insight"},{"key":"1136_CR119","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","volume":"28","author":"JS Miller","year":"2022","unstructured":"Miller, J. S. et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat. Med. 28, 392\u2013400 (2022).","journal-title":"Nat. Med."},{"key":"1136_CR120","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540\u2013551 (2013).","journal-title":"Cell"},{"key":"1136_CR121","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/infdis\/jiaa649","volume":"223","author":"JD Siliciano","year":"2021","unstructured":"Siliciano, J. D. & Siliciano, R. F. Low inducibility of latent human immunodeficiency virus type 1 proviruses as a major barrier to cure. J. Infect. Dis. 223, 13\u201321 (2021).","journal-title":"J. Infect. Dis."},{"key":"1136_CR122","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/M14-1027","volume":"161","author":"TJ Henrich","year":"2014","unstructured":"Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319\u2013327 (2014).","journal-title":"Ann. Intern. Med."},{"key":"1136_CR123","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/COH.0000000000000802","volume":"18","author":"GS Frattari","year":"2023","unstructured":"Frattari, G. S., Caskey, M. & Sogaard, O. S. Broadly neutralizing antibodies for HIV treatment and cure approaches. Curr. Opin. HIV AIDS 18, 157\u2013163 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR124","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMp1613362","volume":"375","author":"M Caskey","year":"2016","unstructured":"Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy. N. Engl. J. Med. 375, 2019\u20132021 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1136_CR125","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368\u2013374 (2022).","journal-title":"Nature"},{"key":"1136_CR126","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375\u2013381 (2022).","journal-title":"Nature"},{"key":"1136_CR127","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1136_CR128","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","volume":"28","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat. Med. 28, 1924\u20131932 (2022).","journal-title":"Nat. Med."},{"key":"1136_CR129","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","volume":"26","author":"A Pegu","year":"2019","unstructured":"Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336\u2013346 (2019).","journal-title":"Cell Host Microbe"},{"key":"1136_CR130","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med. 26, 222\u2013227 (2020).","journal-title":"Nat. Med."},{"key":"1136_CR131","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"1136_CR132","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat. Med. 28, 2424\u20132435 (2022).","journal-title":"Nat. Med."},{"key":"1136_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34171-2","volume":"13","author":"M Rosas-Umbert","year":"2022","unstructured":"Rosas-Umbert, M. et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nat. Commun. 13, 6473 (2022).","journal-title":"Nat. Commun."},{"key":"1136_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002615","volume":"8","author":"J Reece","year":"2012","unstructured":"Reece, J. et al. An \u201cescape clock\u201d for estimating the turnover of SIV DNA in resting CD4+ T cells. PLoS Pathog. 8, e1002615 (2012).","journal-title":"PLoS Pathog."},{"key":"1136_CR135","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224\u2013228 (2013).","journal-title":"Nature"},{"key":"1136_CR136","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360\u2013364 (2018).","journal-title":"Nature"},{"key":"1136_CR137","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1084\/jem.20132494","volume":"211","author":"M Shingai","year":"2014","unstructured":"Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061\u20132074 (2014).","journal-title":"J. Exp. Med."},{"key":"1136_CR138","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","volume":"30","author":"B Julg","year":"2024","unstructured":"Julg, B. et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat. Med. 30, 3534\u20133543 (2024).","journal-title":"Nat. Med."},{"key":"1136_CR139","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1136_CR140","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1084\/jem.20180936","volume":"215","author":"YZ Cohen","year":"2018","unstructured":"Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J. Exp. Med. 215, 2311\u20132324 (2018).","journal-title":"J. Exp. Med."},{"key":"1136_CR141","doi-asserted-by":"publisher","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","volume":"5","author":"SA Riddler","year":"2018","unstructured":"Riddler, S. A. et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect. Dis. 5, ofy242 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"1136_CR142","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/COH.0000000000000800","volume":"18","author":"K Wagh","year":"2023","unstructured":"Wagh, K. & Seaman, M. S. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage. Curr. Opin. HIV AIDS 18, 164\u2013170 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR143","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288\u20131296 (2022).","journal-title":"Nat. Med."},{"key":"1136_CR144","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"1136_CR145","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1128\/JVI.80.10.4971-4977.2006","volume":"80","author":"UM Parikh","year":"2006","unstructured":"Parikh, U. M., Bacheler, L., Koontz, D. & Mellors, J. W. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80, 4971\u20134977 (2006).","journal-title":"J. Virol."},{"key":"1136_CR146","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.chom.2021.04.014","volume":"29","author":"JK Rajashekar","year":"2021","unstructured":"Rajashekar, J. K. et al. Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. Cell Host Microbe 29, 904\u2013916 (2021).","journal-title":"Cell Host Microbe"},{"key":"1136_CR147","first-page":"1900","volume":"25","author":"R Sekaly","year":"2023","unstructured":"Sekaly, R. et al. Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption. Nat. Immunol. 25, 1900\u20131912 (2023).","journal-title":"Nat. Immunol."},{"key":"1136_CR148","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1126\/science.adf7966","volume":"383","author":"SY Lim","year":"2024","unstructured":"Lim, S. Y. et al. Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques. Science 383, 1104\u20131111 (2024).","journal-title":"Science"},{"key":"1136_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01730-22","volume":"96","author":"AP Chandrasekar","year":"2022","unstructured":"Chandrasekar, A. P. et al. The BCL-2 inhibitor venetoclax augments immune effector function mediated by fas ligand, TRAIL, and perforin\/granzyme B, resulting in reduced plasma viremia and decreased HIV reservoir size during acute HIV infection in a humanized mouse model. J. Virol. 96, e0173022 (2022).","journal-title":"J. Virol."},{"key":"1136_CR150","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1128\/JVI.03179-15","volume":"90","author":"NW Cummins","year":"2016","unstructured":"Cummins, N. W. et al. Prime, shock, and kill: priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size. J. Virol. 90, 4032\u20134048 (2016).","journal-title":"J. Virol."},{"key":"1136_CR151","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/COH.0000000000000609","volume":"15","author":"MA Szaniawski","year":"2020","unstructured":"Szaniawski, M. A. & Spivak, A. M. Senotherapeutics for HIV and aging. Curr. Opin. HIV AIDS 15, 83\u201393 (2020).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1136_CR152","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/cells11071222","volume":"11","author":"L Sanchez-Diaz","year":"2022","unstructured":"Sanchez-Diaz, L., Espinosa-Sanchez, A., Blanco, J. R. & Carnero, A. Senotherapeutics in cancer and HIV. Cells 11, 1222 (2022).","journal-title":"Cells"},{"key":"1136_CR153","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1073\/pnas.93.23.13125","volume":"93","author":"DJ Blackbourn","year":"1996","unstructured":"Blackbourn, D. J. et al. Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. Proc. Natl Acad. Sci. USA 93, 13125\u201313130 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1136_CR154","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1099\/jgv.0.000326","volume":"97","author":"D Blazek","year":"2016","unstructured":"Blazek, D., Teque, F., Mackewicz, C., Peterlin, M. & Levy, J. A. The CD8+ cell non-cytotoxic antiviral response affects RNA polymerase II-mediated human immunodeficiency virus transcription in infected CD4+ cells. J. Gen. Virol. 97, 220\u2013224 (2016).","journal-title":"J. Gen. Virol."},{"key":"1136_CR155","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0167-5699(96)10011-6","volume":"17","author":"JA Levy","year":"1996","unstructured":"Levy, J. A., Mackewicz, C. E. & Barker, E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol. Today 17, 217\u2013224 (1996).","journal-title":"Immunol. Today"},{"key":"1136_CR156","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1089\/aid.1992.8.1039","volume":"8","author":"C Mackewicz","year":"1992","unstructured":"Mackewicz, C. & Levy, J. A. CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res. Hum. Retroviruses 8, 1039\u20131050 (1992).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1136_CR157","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1073\/pnas.92.6.2308","volume":"92","author":"CE Mackewicz","year":"1995","unstructured":"Mackewicz, C. E., Blackbourn, D. J. & Levy, J. A. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl Acad. Sci. USA 92, 2308\u20132312 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1136_CR158","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1073\/pnas.0630379100","volume":"100","author":"CE Mackewicz","year":"2003","unstructured":"Mackewicz, C. E., Craik, C. S. & Levy, J. A. The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc. Natl Acad. Sci. USA 100, 3433\u20133438 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1136_CR159","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1128\/JVI.72.12.10165-10170.1998","volume":"72","author":"CE Mackewicz","year":"1998","unstructured":"Mackewicz, C. E., Garovoy, M. R. & Levy, J. A. HLA compatibility requirements for CD8+-T-cell-mediated suppression of human immunodeficiency virus replication. J. Virol. 72, 10165\u201310170 (1998).","journal-title":"J. Virol."},{"key":"1136_CR160","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/cimm.1994.1032","volume":"153","author":"CE Mackewicz","year":"1994","unstructured":"Mackewicz, C. E., Ortega, H. & Levy, J. A. Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol. 153, 329\u2013343 (1994).","journal-title":"Cell Immunol."},{"key":"1136_CR161","first-page":"1261","volume":"81","author":"CE Mackewicz","year":"2000","unstructured":"Mackewicz, C. E., Patterson, B. K., Lee, S. A. & Levy, J. A. CD8+ cell noncytotoxic anti-human immunodeficiency virus response inhibits expression of viral RNA but not reverse transcription or provirus integration. J. Gen. Virol. 81, 1261\u20131264 (2000).","journal-title":"J. Gen. Virol."},{"key":"1136_CR162","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1182\/blood-2002-10-3034","volume":"102","author":"CE Mackewicz","year":"2003","unstructured":"Mackewicz, C. E. et al. Lack of the CD8+ cell anti-HIV factor in CD8+ cell granules. Blood 102, 180\u2013183 (2003).","journal-title":"Blood"},{"key":"1136_CR163","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1128\/jvi.71.4.3120-3128.1997","volume":"71","author":"OO Yang","year":"1997","unstructured":"Yang, O. O. et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71, 3120\u20133128 (1997).","journal-title":"J. Virol."},{"key":"1136_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000747","volume":"6","author":"NR Klatt","year":"2010","unstructured":"Klatt, N. R. et al. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6, e1000747 (2010).","journal-title":"PLoS Pathog."},{"key":"1136_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000748","volume":"6","author":"JK Wong","year":"2010","unstructured":"Wong, J. K. et al. In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6, e1000748 (2010).","journal-title":"PLoS Pathog."},{"key":"1136_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002200","volume":"7","author":"M Elemans","year":"2011","unstructured":"Elemans, M. et al. Why don\u2019t CD8+ T cells reduce the lifespan of SIV-infected cells in vivo? PLoS Comput. Biol. 7, e1002200 (2011).","journal-title":"PLoS Comput. Biol."},{"key":"1136_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003656","volume":"9","author":"NK Seich Al Basatena","year":"2013","unstructured":"Seich Al Basatena, N. K. et al. Can non-lytic CD8+ T cells drive HIV-1 escape? PLoS Pathog. 9, e1003656 (2013).","journal-title":"PLoS Pathog."},{"key":"1136_CR168","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.immuni.2016.08.018","volume":"45","author":"EK Cartwright","year":"2016","unstructured":"Cartwright, E. K. et al. CD8+ lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. Immunity 45, 656\u2013668 (2016).","journal-title":"Immunity"},{"key":"1136_CR169","doi-asserted-by":"publisher","first-page":"e01429","DOI":"10.1128\/JVI.01429-20","volume":"95","author":"M Mavigner","year":"2021","unstructured":"Mavigner, M. et al. CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques. J. Virol. 95, e01429-20 (2021).","journal-title":"J. Virol"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01136-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:06:04Z","timestamp":1751357164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":169,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1038\/s41577-025-01136-7","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"15 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}